stoxline Quote Chart Rank Option Currency Glossary
Merck & Co., Inc. (MRK)
126.09  -3.4 (-2.63%)    05-28 16:00
Open: 128.84
High: 129.08
Volume: 9,705,134
Pre. Close: 129.49
Low: 125.74
Market Cap: 319,362(M)
Technical analysis
2024-05-28 4:54:31 PM
Short term     
Mid term     
Targets 6-month :  151.78 1-year :  155.11
Resists First :  129.95 Second :  132.8
Pivot price 130.09
Supports First :  125.34 Second :  104.29
MAs MA(5) :  129.7 MA(20) :  129.64
MA(100) :  125.62 MA(250) :  114.28
MACD MACD :  0.4 Signal :  0.8
%K %D K(14,3) :  40.6 D(3) :  57.8
RSI RSI(14): 38
52-week High :  133.1 Low :  99.13
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MRK ] has closed below the lower bollinger band by 24.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MRK ] is to continue within current trading range. It is unclear right now based on current values. 40.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 129.22 - 130.27 130.27 - 130.98
Low: 123.57 - 124.73 124.73 - 125.51
Close: 124.58 - 126.37 126.37 - 127.57
Company Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Headline News

Wed, 29 May 2024
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co (NYS - Benzinga

Wed, 29 May 2024
Merck to buy eye-care startup EyeBio for up to $3B - report - Seeking Alpha

Wed, 29 May 2024
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech - Financial Times

Tue, 28 May 2024
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports - MSN

Tue, 28 May 2024
Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports - Reuters

Tue, 28 May 2024
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports - Yahoo! Voices

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - General
Shares Out 2,530 (M)
Shares Float 2,530 (M)
Held by Insiders 0 (%)
Held by Institutions 77.9 (%)
Shares Short 18,750 (K)
Shares Short P.Month 19,590 (K)
Stock Financials
EPS 0.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.93
Profit Margin 3.7 %
Operating Margin 42.4 %
Return on Assets (ttm) 10.2 %
Return on Equity (ttm) 5.3 %
Qtrly Rev. Growth 8.8 %
Gross Profit (p.s.) 0
Sales Per Share 24.26
EBITDA (p.s.) 8.38
Qtrly Earnings Growth 68.5 %
Operating Cash Flow 14,760 (M)
Levered Free Cash Flow 9,590 (M)
Stock Valuations
PE Ratio 140.1
PEG Ratio 0.2
Price to Book value 7.91
Price to Sales 5.19
Price to Cash Flow 21.61
Stock Dividends
Dividend 0.76
Forward Dividend 0
Dividend Yield 0.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android